Select Your Region
Global
A clinical trial to compare faricimab with aflibercept in people with diabetic macular edema. (RHINE)
A Study to Evaluate the Efficacy and Safety of RO6867461 in Participants With Diabetic Macular Edema
- Eye Disorder
- Diabetic Macular Edema
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Completed
This trial runs in
Cities
- Aalborg
- aan
- Ankara
- Augusta
- Aurora
- Austin
- Bakersfield
- Barcelona
- bei-jing-shi
- Beijing
- Belfast
- Beverly Hills
- Binningen
- blagny-sur-vingeanne
- Bloomfield
- Boisbriand
- Boston
- Bradford
- Braga
- Bristol
- Budapest
- Buenos Aires
- Burjasot
- Bydgoszcz
- Calgary
- Camberley
- Canterbury
- Chang Wat Chiang Mai
- chang-chun-shi
- Charlottesville
- Chattanooga
- Cheboksary
- Cheng Du Shi
- chong-qing-shi
- Chongqing
- Cleveland
- Coimbra
- Colorado Springs
- Créteil
- czerwionka-leszczyny
- Dresden
- East Melbourne
- Firenze
- Fort Lauderdale
- Fort Myers
- Freiburg im Breisgau
- Fullerton
- Gdańsk
- Glostrup
- Gloucester
- Goiás
- Grand Rapids
- Great Yarmouth
- Greenville
- guang-zhou-shi
- Halifax
- Hauppauge
- Hlavní město Praha
- Homburg
- Hong Kong Island
- Irkutsk
- İstanbul
- Kazan
- Knoxville
- Kocaeli
- Kraków
- Krung Thep Maha Nakhon
- Královéhradecký kraj
- L'Hospitalet de Llobregat
- Ladson
- Las Vegas
- Leeds
- Lisboa
- Liverpool
- Lombardy
- London
- Los Angeles
- Lyon
- Madrid
- Magdeburg
- Manchester
- Melbourne
- Mendoza
- Montréal
- Mountain View
- München
- Nanjing
- Nashville
- Nedlands
- negrar-di-valpolicella
- New York
- Newcastle upon Tyne
- Novosibirsk
- Oak Forest
- Oceanside
- Ostrava
- Ottawa
- Oviedo
- Palm Beach Gardens
- Pamplona
- Paris
- Philadelphia
- Phoenix
- Pisa
- Plantation
- Porto Alegre
- Richmond
- Rochester
- Roma
- Rosario
- Roskilde
- Rowville
- Rzeszów
- Sacramento
- Saint-Cyr-sur-Loire
- Sant Cugat del Vallès
- Santa Barbara
- Santa Catarina
- Seongnam-si
- Seoul
- shang-hai-shi
- Silverdale
- Singapore
- Slingerlands
- sokolov-1
- Southampton
- Southlake
- Springdale
- Springfield
- St. Petersburg
- Strathfield
- Sunderland
- Sydney
- São Paulo
- Taipei City
- Taoyuan City
- Tarnowskie Góry
- The Woodlands
- tian-jin-shi
- Toronto
- Toulouse
- Towson
- Udine
- uxbridge
- Valladolid
- València
- Vancouver
- Walnut Creek
- Warszawa
- Waterford
- wen-zhou-shi
- west-columbia
- Westmead
- wu-xi-shi
- Würzburg
Trial Identifier:
NCT03622593 2017-005105-12 GR40398
Trial Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Hoffmann-La Roche
Sponsor
Phase 3
Phase
NCT03622593, GR40398, 2017-005105-12
Trial Identifier
Aflibercept, Faricimab, Sham Procedure
Treatments
Diabetic Macular Edema
Condition
Official Title
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
Eligibility Criteria
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
- Hemoglobin A1c (HbA1c) of less than or equal to (≤)10% within 2 months prior to Day 1
- Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea
- Decreased visual acuity attributable primarily to DME
- Ability and willingness to undertake all scheduled visits and assessments
- For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the final dose of study treatment
Exclusion Criteria
- Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
- Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
- Currently pregnant or breastfeeding, or intend to become pregnant during the study
- Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye
- Any intraocular or periocular corticosteroid treatment within 6 months prior to Day 1 to the study eye
- Prior administration of IVT faricimab in either eye
- Active intraocular or periocular infection or active intraocular inflammation in the study eye
- Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
- Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
- Other protocol-specified inclusion/exclusion criteria may apply
For the latest version of this information please go to www.forpatients.roche.com